STOCK TITAN

Incyte Genomics (INCY) Stock News, Dec 2020-Feb 2021

INCY NASDAQ

Incyte Corporation (INCY) reports developments for a biopharmaceutical business focused on hematology, oncology, and inflammation and autoimmunity. Recurring updates cover commercial medicines such as Jakafi, Jakafi XR, and Opzelura, regulatory decisions for approved and investigational therapies, and clinical data across blood cancers, graft-versus-host disease, dermatology, and solid tumors.

Company news also includes financial results, product revenue trends, pipeline progress, investor conference participation, executive appointments, equity inducement awards, and international regulatory updates tied to hematology and oncology therapies.

Rhea-AI Summary

Incyte will present at the Cowen 41st Annual Health Care Conference on March 3, 2021, at 2:00 p.m. EST. The event will be available via a live webcast on Investor.Incyte.com, with a replay accessible for 90 days post-event. As a biopharmaceutical company based in Wilmington, Delaware, Incyte focuses on addressing serious medical needs through the development and commercialization of innovative therapeutics. For more information, visit Incyte.com.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.21%
Tags
conferences
-
Rhea-AI Summary

Incyte reported robust financial results for Q4 and full year 2020, highlighting strong revenue growth fueled by Jakafi's demand and successful launches of Monjuvi and Pemazyre. The company anticipates regulatory decisions on seven new applications in 2021, including potential FDA approval for ruxolitinib cream by mid-year. Key clinical advancements include ongoing Phase 3 trials for ruxolitinib combined with parsaclisib for myelofibrosis and a new collaboration with Cellenkos for innovative treatments in hematology.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.44%
Tags
-
Rhea-AI Summary

Incyte announced a positive opinion from the European Medicines Agency's CHMP for the conditional marketing authorization of pemigatinib in treating adults with unresectable locally advanced or metastatic cholangiocarcinoma with FGFR2 fusion after at least one systemic therapy. The CHMP's recommendation, based on the FIGHT-202 study data, is now under review by the European Commission. If granted, pemigatinib will be the first targeted therapy for this condition in Europe, enhancing treatment options for patients facing poor prognoses.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.67%
Tags
none
Rhea-AI Summary

Incyte announced the FDA's acceptance for Priority Review of its Biologics License Application for retifanlimab, an intravenous PD-1 inhibitor for treating locally advanced or metastatic squamous cell carcinoma of the anal canal (SCAC). The BLA is based on data from the Phase 2 POD1UM-202 trial, showing a 14% objective response rate in previously treated patients. Retifanlimab has Orphan Drug Designation, and Priority Review shortens the FDA review period by four months, with a target action date set for July 25, 2021.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.25%
Tags
none
-
Rhea-AI Summary

Incyte has announced a conference call to discuss its fourth quarter and year-end 2020 financial results, scheduled for February 9, 2021, at 8:00 a.m. ET. The press release will be available earlier that day at 7:00 a.m. ET. Participants can join via a domestic dial-in number (877-407-3042) or an international line (201-389-0864), using conference ID 13715042. A replay of the call will be accessible for 30 days. Incyte is dedicated to addressing serious medical needs through the development of proprietary therapeutics.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.75%
Tags
conferences earnings
-
Rhea-AI Summary

Incyte (Nasdaq: INCY) has partnered with Cellenkos, Inc. to study the combination of ruxolitinib and CK0804 for treating myelofibrosis (MF). This collaboration includes an option for Incyte to acquire exclusive rights to CK0804 and its variants. The Phase 1b study will be funded by Incyte and operationalized by Cellenkos, with a potential $20 million licensing fee and up to $294.5 million in milestone payments. This initiative aligns with Incyte's LIMBER program aimed at enhancing treatments for myeloproliferative neoplasms.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.15%
Tags
none
Rhea-AI Summary

Incyte announced that the Phase 3 RUXCOVID study of ruxolitinib for treating COVID-19 associated cytokine storm did not meet its primary endpoint. Data indicated no significant reduction in severe complications or mortality among patients receiving ruxolitinib compared to standard-of-care alone (12.0% vs. 11.8%). Secondary endpoints also showed no clinically relevant benefits. Despite these disappointing results, ruxolitinib was generally well tolerated. Ongoing analyses will assess the implications for other studies. The results do not affect ongoing non-COVID-19 trials or approved uses of ruxolitinib.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.78%
Tags
clinical trial covid-19
-
Rhea-AI Summary

Eli Lilly and Incyte announced publication of peer-reviewed results from the Adaptive COVID-19 Treatment Trial (ACTT-2) in The New England Journal of Medicine. The Phase 3 study demonstrated that baricitinib, combined with remdesivir, shortened recovery times and lowered the risk of progression to ventilation or death in hospitalized COVID-19 patients. This supports the emergency use authorization (EUA) granted by the FDA on Nov. 19. Though not FDA-approved for COVID-19, baricitinib is authorized for use in hospitalized patients requiring supplemental oxygen.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.91%
Tags
covid-19
-
Rhea-AI Summary

Incyte will present at the 39th Annual J. P. Morgan Virtual Healthcare Conference on January 11, 2021, at 7:30 a.m. EST. The presentation will be available for live streaming at Investor.Incyte.com and can be replayed for 90 days. Incyte is a biopharmaceutical company based in Wilmington, Delaware, dedicated to addressing serious unmet medical needs through proprietary therapeutics.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.28%
Tags
conferences
Rhea-AI Summary

Incyte and MorphoSys AG presented preliminary data from the firstMIND study at the 62nd ASH Annual Meeting, focusing on tafasitamab and lenalidomide combined with R-CHOP for newly diagnosed DLBCL patients. Results showed an acceptable tolerability profile, with serious neutropenia and thrombocytopenia more frequent in the combination arm. Objective response rates were high, with 91.1% of patients responding after three cycles. A Phase 3 trial, frontMIND, will evaluate this combination as first-line treatment. Long-term analyses from the L-MIND study also indicated durable responses with no unexpected safety signals.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.10%
Tags
none

FAQ

What is the current stock price of Incyte Genomics (INCY)?

Incyte Genomics (INCY) last closed at $119.09.

What is the market cap of Incyte Genomics (INCY)?

The market cap of Incyte Genomics (INCY) is approximately $24.3B.